摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-二乙基哌啶 | 61843-59-2

中文名称
1,3-二乙基哌啶
中文别名
——
英文名称
1,3-diethyl-piperidine
英文别名
1,3-Diaethyl-piperidin;1,3-Diethylpiperidine
1,3-二乙基哌啶化学式
CAS
61843-59-2
化学式
C9H19N
mdl
——
分子量
141.257
InChiKey
MZMHDMCGCUWTDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted Sulfonamide Compounds
    申请人:OBERBOERSCH Stefan
    公开号:US20080249128A1
    公开(公告)日:2008-10-09
    Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and/or other disorders and/or disease states.
    用具有激肽酶受体(B1R)调节活性的磺胺化合物替代;制备这些化合物的方法,包括这些化合物的药物组合物,以及使用这些化合物治疗或抑制疼痛和/或其他疾病状态的方法。
  • [EN] SULFONYLUREA DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONYLURÉE ET LEURS UTILISATIONS
    申请人:NODTHERA LTD
    公开号:WO2020249664A1
    公开(公告)日:2020-12-17
    The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    本公开涉及式(I)化合物及其前药、药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟,并可用于治疗炎症、自身炎症和自身免疫疾病以及癌症等炎症小体活性涉及的疾病。
  • Substituted Amide Compounds
    申请人:Oberboersch Stefan
    公开号:US20080306084A1
    公开(公告)日:2008-12-11
    Substituted amide compounds corresponding to formula I: processes for preparing them, pharmaceutical compositions containing these compounds, and the use of substituted amide derivatives for the preparation of medicaments for the treatment of pain and various other conditions.
    将与式I相对应的取代酰胺化合物: 制备它们的方法,含有这些化合物的药物组合物,以及利用取代酰胺衍生物制备用于治疗疼痛和其他各种疾病的药物的用途。
  • ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS
    申请人:Failli Amedeo A.
    公开号:US20090042874A1
    公开(公告)日:2009-02-12
    The invention provides compounds of the Formula: that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    该发明提供了下列式的化合物,该化合物对于治疗抑郁症(包括但不限于重度抑郁障碍、儿童抑郁症和心境不良)、焦虑症、恐慌症、创伤后应激障碍、经前期失调症(也称为经前综合征)、注意力缺陷多动障碍(有和没有过度活跃)、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖症、饮食紊乱如厌食症、贪食症、潮红、可卡因和酒精成瘾、性功能障碍及相关疾病具有有益作用。
  • CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION
    申请人:Olson Richard E.
    公开号:US20100009965A1
    公开(公告)日:2010-01-14
    This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.
    本发明涉及具有公式(I)的新型环状马隆酰胺,其药物组成物和使用方法。这些新化合物抑制淀粉样前体蛋白的加工,更具体地抑制Aβ-肽的产生,从而防止神经沉积物的淀粉样蛋白形成。更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经疾病,如阿尔茨海默病和唐氏综合症。
查看更多